|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0026565,
umls-concept:C0031809,
umls-concept:C0087111,
umls-concept:C0155626,
umls-concept:C0205225,
umls-concept:C0205421,
umls-concept:C0233820,
umls-concept:C0522523,
umls-concept:C1174136,
umls-concept:C1522318,
umls-concept:C1948041
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-3-16
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Prior studies demonstrate a direct relationship between treatment delays to primary percutaneous intervention and mortality in patients with ST-segment elevation myocardial infarction (STEMI). This analysis compared the relationship of symptom onset-to-balloon time and door-to-balloon time on mortality in patients with STEMI.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1941-7705
|
|
pubmed:author |
pubmed-author:ArmstrongPaul WPW,
pubmed-author:AylwardPhilip EPE,
pubmed-author:GrangerChristopher BCB,
pubmed-author:HolmesDavidD,
pubmed-author:HudsonMichael PMP,
pubmed-author:MahaffeyKenneth WKW,
pubmed-author:O'NeilWilliam WWW,
pubmed-author:RuzylloWitoldW,
pubmed-author:StebbinsAmanda LAL,
pubmed-author:WeaverW DouglasWD,
pubmed-author:WidimskyPetrP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
183-92
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21304097-Age Factors,
pubmed-meshheading:21304097-Aged,
pubmed-meshheading:21304097-Angioplasty, Balloon, Coronary,
pubmed-meshheading:21304097-Antibodies, Monoclonal,
pubmed-meshheading:21304097-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21304097-Complement C5,
pubmed-meshheading:21304097-Electrocardiography,
pubmed-meshheading:21304097-Female,
pubmed-meshheading:21304097-Humans,
pubmed-meshheading:21304097-Male,
pubmed-meshheading:21304097-Middle Aged,
pubmed-meshheading:21304097-Myocardial Infarction,
pubmed-meshheading:21304097-Sex Factors,
pubmed-meshheading:21304097-Single-Chain Antibodies,
pubmed-meshheading:21304097-Time Factors,
pubmed-meshheading:21304097-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
|
|
pubmed:affiliation |
Henry Ford Heart & Vascular Institute, Detroit, MI 48202, USA. mhudson1@hfhs.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
